SCHEMBL2378490

SCHEMBL2378490

CCOCOCC(CC(C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 0.72
MMP9 P14780 6/20 0.72
MMP12 P39900 4/20 0.72
ADAM17 P78536 1/20 0.44
MMP1 P03956 3/20 0.42
MMP13 P45452 3/20 0.41
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HDAC3 O15379 1/20 0.40
TAS1R3 Q7RTX0 2/20 0.40
TAS1R1 Q7RTX1 2/20 0.40
PPARG P37231 2/20 0.39
NPSR1 Q6W5P4 1/20 0.38
UTS2R Q9UKP6 1/20 0.38
PPARA Q07869 1/20 0.38
MMP3 P08254 1/20 0.38
MMP7 P09237 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3043179 1.00 MMP2 (0.72) MMP2MMP9MMP12ADAM17MMP1
SCHEMBL5998355 1.00 MMP2 (0.72) MMP2MMP9MMP12ADAM17MMP1
SCHEMBL5998467 1.00 MMP2 (0.72) MMP2MMP9MMP12ADAM17MMP1
SCHEMBL5998377 0.91 MMP2 (0.73) MMP2MMP9MMP12ADAM17MMP1
SCHEMBL5998380 0.91 MMP2 (0.73) MMP2MMP9MMP12ADAM17MMP1
SCHEMBL7739292 0.91 MMP2 (0.57) MMP2MMP9MMP12MMP1MMP13
SCHEMBL7739285 0.91 MMP2 (0.57) MMP2MMP9MMP12MMP1MMP13
SCHEMBL5998707 0.90 MMP2 (0.69) MMP2MMP9MMP12ADAM17MMP1
SCHEMBL5998713 0.90 MMP2 (0.69) MMP2MMP9MMP12ADAM17MMP1
SCHEMBL5999313 0.90 MMP9 (0.69) MMP2MMP9MMP12ADAM17MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060014835-A1 Therapeutic agent for chronic obstructive pulmonary disease ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-19 US claimed
US-20050165112-A1 Therapeutic agent for inflammatory intestinal diseases containing hydroxamic acid compound as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-07-28 US claimed
EP-1552824-A1 THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE ONO PHARMACEUTICAL CO., LTD. (JP) 2005-07-13 EP claimed
EP-1510209-A1 THERAPEUTIC AGENT FOR INFLAMMATORY INTESTINAL DISEASES CONTAINING HYDROXAMIC ACID COMPOUND AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2005-03-02 EP claimed
US-20040242694-A1 administering N-hydroxy-5-hydroxy-2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide or derivatives for treating /preventing cardiac failure and/or cardiac hypertrophy ONO PHARMACEUTICAL CO., LTD. (JP) 2004-12-02 US claimed
US-20040198831-A1 Remedial agent for arthrosis deformans ONO PHARMACEUTICAL CO., LTD. (JP) 2004-10-07 US claimed
US-20040152785-A1 Novel crystal of n-hydroxy-2 (s)-methyl-5-ethoxymethoxy-4(s)-[n-(4-phenoxyphenylcarbonyl)amino] pentanamide, process for their production and medicines containing the crystals as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2004-08-05 US claimed
EP-1421934-A1 REMEDIAL AGENT FOR ARTHROSIS DEFORMANS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-05-26 EP claimed
EP-1419767-A1 REMEDIAL AGENT FOR CARDIAC FAILURE ONO PHARMACEUTICAL CO., LTD. (JP) 2004-05-19 EP claimed
US-20040068015-A1 Remedies for diseases due to stenotic lesions of blood vessel ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-08 US claimed
EP-1316547-A1 NOVEL CRYSTALS OF N-HYDROXY-2(S)-METHYL-5-ETHOXYMETHOXY -4(S)- N-(4-PHENOXYPHENYLCARBONYL)AMINO]PENTANAMIDE, PROCESS FOR THEIR PRODUCTION AND MEDICINES CONTAINING THE CRYSTALS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2003-06-04 EP claimed
EP-1275385-A1 REMEDIES FOR DISEASES DUE TO STENOTIC LESIONS OF BLOOD VESSEL ONO PHARMACEUTICAL CO., LTD. (JP) 2003-01-15 EP claimed
US-6420427-B1 PREVENTION AND/OR TREATMENT OF RHEUMATOID DISEASES, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS, INTERSTITIAL NEPHRITIS, ARTERIOSCLEROSIS, PULMONARY EMPHYSEMA, CIRRHOSIS, CORNEA INJURY ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1024134-A1 AMINOBUTANOIC ACID DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 2000-08-02 EP claimed
EP-2681209-B1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS AQUILUS PHARMACEUTICALS INC (US) 2018-05-09 EP disclosed
EP-2681209-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS Aquilus Pharmaceuticals, Inc (US) 2014-01-08 EP disclosed
US-20130338116-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES SUCHOLEIKI IRVING (US) 2013-12-19 US disclosed
US-6420427-B1 PREVENTION AND/OR TREATMENT OF RHEUMATOID DISEASES, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS, INTERSTITIAL NEPHRITIS, ARTERIOSCLEROSIS, PULMONARY EMPHYSEMA, CIRRHOSIS, CORNEA INJURY ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
WO-2001058440-A1 REMEDIES FOR DEGENERATIVE ARTHRITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2001-08-16 WO disclosed
EP-1024134-A1 AMINOBUTANOIC ACID DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 2000-08-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165112-A1 Therapeutic agent for inflammatory intestinal diseases containing hydroxamic acid compound as active ingredient SI, SLC10A2, FABP2 MMP2 173/4885MMP9 89/4885MMP12 38/4885
US-20040198831-A1 Remedial agent for arthrosis deformans MMP1, MMP3, MMP11 MMP2 14/4885MMP9 10/4885MMP12 20/4885
US-20040068015-A1 Remedies for diseases due to stenotic lesions of blood vessel MMP11, MMP1, MMP8 MMP2 19/4885MMP9 4/4885MMP12 23/4885
US-20040242694-A1 administering N-hydroxy-5-hydroxy-2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide or derivatives for treating /preventing cardiac failure and/or cardiac hypertrophy TNNT2, NPR1, MMP1 MMP2 20/4885MMP9 12/4885MMP12 65/4885
US-20040152785-A1 Novel crystal of n-hydroxy-2 (s)-methyl-5-ethoxymethoxy-4(s)-[n-(4-phenoxyphenylcarbonyl)amino] pentanamide, process for their production and medicines containing the crystals as the active ingredient MMP1, MMP2, MMP9 MMP2 2/4885MMP9 3/4885MMP12 29/4885
US-20060014835-A1 Therapeutic agent for chronic obstructive pulmonary disease HAO2, MMP8, HCAR2 MMP2 23/4885MMP9 139/4885MMP12 21/4885
US-20130338116-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES MMP9, MMP10, MMP3 MMP2 5/4885MMP9 1/4885MMP12 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.